grp 78

GRP78-IN-1 displays interactions with specific residues on the GRP78 protein with a binding energy of -8.07 kcal/mol. This compound possesses potent cytotoxic and anti-proliferative effects on cancer cells, particularly demonstrating promising apoptosis in breast cancer cells and wound healing properties [1].

GRP78-IN-2 is a glucose regulatory protein 78 (GRP78) inhibitor that preferentially targets GRP78 on the cell surface and has significant anti-angiogenic and anti-cancer effects without affecting other normal cells.

GRP78-IN-3, a potent small-molecule-competitive inhibitor of Hsp70 substrate binding and is a selective Grp78 (HSPA5) inhibitor with an IC50 of 0.59 μM. GRP78-IN-3 is 7-fold selective for HspA5 compared to HspA9 (IC50 of 4.3 μM) and >20-fold selective for HspA5 compared to HspA2 (IC50 of 13.9 μM).

Anti-Human/Mouse GRP78 Antibody (C38) is a mouse IgG2b kappa isotype antibody designed for in vivo use, specifically targeting GRP78. The recommended isotype control for this antibody is Mouse IgG2b kappa, Isotype Control.

Anti-Human/Mouse GRP78 Antibody (N88) is an IgG1, κ antibody inhibitor derived from mice, designed to target human or mouse GRP78.

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.

BiP inducer X (BIX) is a selective inducer of immunoglobulin heavy chain binding protein (BiP)/GRP78 and an ER chaperone inducer. BiP inducer X prevents cell death in neurons and retinal cell lines.

Questiomycin A is an antibiotic produced in crème fraiche with antibacterial and anticancer activities. Questiomycin A suppresses expression of GRP78, a cell-protective ER chaperone protein.

HA15 targets specifically BiP/GRP78/HSPA5. HA15 exhibits anti-cancerous activity on all melanoma cells tested, including cells isolated from patients and cells that developed resistance to BRAF inhibitors.

YUM70 is a potent and selective inhibitor of glucose-regulated protein 78 (GRP78), with an IC50 of 1.5 μM for inhibiting GRP78 ATPase activity of the full-length protein. It induces endoplasmic reticulum (ER) stress-mediated apoptosis in pancreatic cancer.

Dehydroeffusol (Dehydro Effusol) possesses anti-cancer, anxiolytic and sedative properties. Dehydroeffusol inhibits gastric cancer cell growth and tumorigenicity by selectively inducing tumor-suppressive endoplasmic reticulum stress and a moderate apoptosis.